The mutation landscape of multiple cancer predisposition genes in Chinese familial/hereditary breast cancer families

被引:4
|
作者
Dong, Li [1 ]
Zhang, Hailian [2 ,3 ,4 ]
Zhang, Huan [3 ]
Ye, Yingnan
Cheng, Yanan [1 ]
Li, Lijuan [3 ]
Wei, Lijuan [3 ]
Han, Lei [1 ]
Cao, Yandong [5 ]
Li, Shixia [2 ,3 ]
Hao, Xishan [1 ,3 ]
Liu, Juntian [2 ,3 ]
Yu, Jinpu [1 ]
机构
[1] Tianjin Med Univ, Canc Mol Diagnost Core,Key Lab Breast Canc Preven, Canc Inst & Hosp,Tianjins Clin Res Ctr Canc,Minis, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin 300060, Peoples R China
[2] Tianjin Med Univ, Dept Breast Canc 2, Canc Inst & Hosp,Tianjins Clin Res Ctr Canc, Natl Clin Res Ctr Canc,Minist Educ, Tianjin 300060, Peoples R China
[3] Tianjin Med Univ, Canc Prevent Ctr, Canc Inst & Hosp,Tianjins Clin Res Ctr Canc, Natl Clin Res Ctr Canc,Minist Educ, Tianjin 300060, Peoples R China
[4] Tianjin Third Cent Hosp, Dept Oncol,Tianjin Inst Hepatobiliary Dis, Tianjin Key Lab Artificial Cell, Artificial Cell Engn Technol Res Ctr Publ Hlth Mi, Tianjin 300170, Peoples R China
[5] Analyses Technol Co Ltd, Beijing 102600, Peoples R China
基金
中国国家自然科学基金;
关键词
Familial breast cancer; predisposition genes; DNA damage repair genes; clinical features; NONPOLYPOSIS COLORECTAL-CANCER; GERMLINE MUTATIONS; BRCA2; MUTATIONS; EARLY-ONSET; DNA-REPAIR; CELL-CYCLE; JOINT CONSENSUS; RISK-ASSESSMENT; WOMEN; SUSCEPTIBILITY;
D O I
10.20892/j.issn.2095-3941.2021.0011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Approximately 5%-10% of breast cancer (BC) patients display familial traits that are genetically inherited among the members of a family. The purpose of this study was to profile the germline mutations in 43 genes with different penetration rates and their correlations with phenotypic traits in Chinese familial BC families. Methods: Ion Torrent S5 (TM)-based next generation sequencing was conducted on 116 subjects from 27 Chinese familial BC families. Results: Eighty-one germline mutations in 27 BC predisposition genes were identified in 82.8% (96/116) of the cases. Among these, 80.8% of the mutated genes were related to DNA damage repair. Fourteen possible disease-causing variants were identified in 13 of 27 BC families. Only 25.9% (7/27) of the BC families exhibited hereditary deficiency in BRCA1/2 genes, while 22.2% of the BC families exhibited defects in non-BRCA genes. In all, 41.7% (40/96) of the mutation carriers had BRCA mutations, 88.5% (85/96) had non-BRCA mutations, and 30.2% (29/96) had both BRCA and non-BRCA mutations. The BC patients with BRCA mutations had a higher risk of axillary lymph node metastases than those without mutations (P < 0.05). However, the BC patients with non-BRCA mutations frequently had a higher occurrence of benign breast diseases than those without mutations (P < 0.05). Conclusions: In addition to BRCA1/2, genetic variants in non-BRCA DNA repair genes might play significant roles in the development of familial/hereditary BC. Therefore, profiling of multiple BC predisposition genes should be more valuable for screening potential pathogenic germline mutations in Chinese familial/hereditary BC.
引用
收藏
页码:850 / 870
页数:21
相关论文
共 50 条
  • [31] Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China
    Cao, A-Yong
    Hu, Zhen
    Shao, Zhi-Ming
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (01) : 271 - 272
  • [32] The pathological and molecular genetic landscape of the hereditary renal cancer predisposition syndromes
    Al-Obaidy, Khaleel, I
    Alruwaii, Zainab, I
    Williamson, Sean R.
    Cheng, Liang
    HISTOPATHOLOGY, 2022, 81 (01) : 15 - 31
  • [33] Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients
    Crawford, Beth
    Adams, Sophie B.
    Sittler, Taylor
    van den Akker, Jeroen
    Chan, Salina
    Leitner, Ofri
    Ryan, Lauren
    Gil, Elad
    van't Veer, Laura
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 383 - 390
  • [34] Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer
    Rummel, Seth K.
    Lovejoy, Leann
    Shriver, Craig D.
    Ellsworth, Rachel E.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (03) : 593 - 601
  • [35] The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition
    Moretta, Jessica
    Berthet, Pascaline
    Bonadona, Valerie
    Caron, Olivier
    Cohen-Haguenauer, Odile
    Colas, Chrystelle
    Corsini, Carole
    Cusin, Veronica
    De Pauw, Antoine
    Delnatte, Capucine
    Dussart, Sophie
    Jamain, Christophe
    Longy, Michel
    Luporsi, Elisabeth
    Maugard, Christine
    Tan Dat Nguyen
    Pujol, Pascal
    Vaur, Dominique
    Andrieu, Nadine
    Lasset, Christine
    Nogues, Catherine
    BULLETIN DU CANCER, 2018, 105 (10) : 907 - 917
  • [36] Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes
    Narod, Steven A.
    Rodriguez, Adriana A.
    SALUD PUBLICA DE MEXICO, 2011, 53 (05): : 420 - 429
  • [37] Hereditary and Familial Colon Cancer
    Jasperson, Kory W.
    Tuohy, Therese M.
    Neklason, Deborah W.
    Burt, Randall W.
    GASTROENTEROLOGY, 2010, 138 (06) : 2044 - 2058
  • [38] How I approach hereditary cancer predisposition in a child with cancer
    Kuhlen, Michaela
    Wieczorek, Dagmar
    Siebert, Reiner
    Fruehwald, Michael C.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (11)
  • [39] The complex genetic landscape of familial breast cancer
    Lorenzo Melchor
    Javier Benítez
    Human Genetics, 2013, 132 : 845 - 863
  • [40] Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
    Couch, Fergus J.
    Shimelis, Hermela
    Hu, Chunling
    Hart, Steven N.
    Polley, Eric C.
    Na, Jie
    Hallberg, Emily
    Moore, Raymond
    Thomas, Abigail
    Lilyquist, Jenna
    Feng, Bingjian
    McFarland, Rachel
    Pesaran, Tina
    Huether, Robert
    LaDuca, Holly
    Chao, Elizabeth C.
    Goldgar, David E.
    Dolinsky, Jill S.
    JAMA ONCOLOGY, 2017, 3 (09) : 1190 - 1196